Building a longevity biomarker panel: what brands should include

A longevity biomarker panel is a curated set of blood tests brands use to baseline members and track change over time. Start with metabolic and cardiovascular markers clinicians already use for risk assessment, add hormone, thyroid, or nutrient tests only when your model needs them, and keep the first panel lean enough to retest.
What a longevity biomarker panel is for brands
For a brand or clinic, a panel is a product design choice as much as a clinical one. Members expect a clear set of markers, the same kit and lab every round, and results that land in your coaching app or EMR. The panel should answer a few program questions: which risks are you screening for, which lifestyle or treatment changes will you coach against, and which markers will you retest on a fixed cadence.
That framing keeps the conversation grounded. Blood chemistry can inform cardiovascular risk, glycemic status, thyroid function, and selected nutrients. It does not, by itself, prove that someone will live longer. Programs that oversell “longevity proof” from a single draw set false expectations and make clinical oversight harder.
IHDLab’s longevity lab testing work with clinics and optimization brands is built around that repeatable loop: a branded kit, in-house CLIA testing, and results routed back into the program. The markers below map to categories those programs commonly request.
Core metabolic and cardiovascular markers
Most first panels start here because the clinical rationale is well documented and the results support coaching that members already understand—lipids, blood sugar, and inflammation context.
Lipids. A lipid panel (total cholesterol, LDL, HDL, and triglycerides) remains a cornerstone of cardiovascular risk assessment. The American Heart Association notes that high cholesterol often has no symptoms and that a simple blood test shows where levels sit. The NHLBI likewise describes how elevated LDL contributes to plaque buildup. Lipid results also feed 10-year CVD risk estimates that clinicians use when discussing statin therapy. The USPSTF’s 2022 recommendation on statin use for primary prevention centers on adults 40–75 with cardiovascular risk factors and an estimated 10-year risk at or above 10%, with selective discussion in the 7.5–10% range. Brands do not diagnose or prescribe from a kit alone; they design the panel so ordered clinicians have the numbers they need.
Glycemic markers. Hemoglobin A1c and fasting glucose help identify prediabetes and diabetes risk. The CDC outlines A1c cutoffs used in practice (below 5.7% normal, 5.7–6.4% prediabetes, 6.5% or above diabetes) and notes that type 2 diabetes and prediabetes often lack early symptoms. The USPSTF recommends screening for prediabetes and type 2 diabetes in adults 35–70 who have overweight or obesity. Including A1c on a baseline panel gives programs a shared language for nutrition and activity coaching.
Inflammation context. High-sensitivity C-reactive protein (hs-CRP) is a nonspecific marker of inflammation. MedlinePlus explains that CRP rises with many conditions and that results need clinical interpretation alongside other findings. Brands sometimes add hs-CRP for trend context; it should not be sold as a standalone “longevity score.”
Basic chemistry and blood counts. A comprehensive metabolic panel and CBC give liver and kidney context, electrolytes, and anemia signals that clinicians expect before interpreting hormones or nutrients. The NHLBI’s overview of heart disease risk factors underscores how blood pressure, cholesterol, diabetes, and related risks stack; lab work complements those clinical assessments rather than replacing them.
The Endocrine Society’s lipid management guideline for patients with endocrine disorders is a useful reminder that endocrine disease and lipids often travel together—another reason programs keep metabolic and hormone planning under licensed clinical oversight.
Hormone, thyroid, and nutrient add-ons brands often consider
After the metabolic core, brands usually choose add-ons that match their clinical model.
Thyroid. TSH (often with free T4) screens for hypothyroidism and related patterns. The NIDDK describes common symptoms and notes that blood tests confirm the diagnosis. Optimization programs that coach energy, weight, or cold intolerance often include thyroid markers so clinicians can rule in or out a treatable contributor.
Sex hormones and related binders. Testosterone, free androgen index or free testosterone where available, SHBG, estradiol, progesterone, DHEA, and cortisol appear on many men’s and women’s optimization menus. These are sensitive tests: timing (cycle day, time of day), medications, and clinical history matter. Include them when your supervising clinicians will act on the results—not as a marketing checklist.
Micronutrients. 25-hydroxyvitamin D is the common nutrient add-on. The NIH Office of Dietary Supplements explains that serum 25(OH)D is the main status indicator and that the Food and Nutrition Board considers levels of 50 nmol/L (20 ng/mL) or more sufficient for most people, with deficiency risk rising below 30 nmol/L (12 ng/mL). Iron studies, B12, and related micronutrients fit programs that already counsel on diet or supplementation. For supplement brands, biomarkers work best when they validate a specific claim pathway your clinicians and compliance team have already approved—not when they invent one.
Omega-3 and specialty screening. Some longevity menus add omega-3 indices or age- and sex-specific screens (for example PSA in appropriate populations). Treat these as optional modules tied to clinical protocols rather than defaults for every member.
What not to cram into a first panel
A first panel that tries to measure everything creates three problems: higher kit cost and drop-off, noisier coaching narratives, and results nobody is prepared to act on.
Skip research-only or poorly standardized assays until your medical directors have a written protocol. Avoid duplicative markers that tell the same story twice. Do not promise that any combination of labs will “optimize lifespan.” Frame the panel as risk screening, progress tracking, and clinical decision support under licensed ordering providers.
A practical rule: every marker on the menu should have an owner (who interprets it), a member-facing explanation, and a retest plan.
Retesting cadence, briefly
Longevity programs live on repeat data. Baseline once, intervene, then retest the same markers on a schedule your clinicians set—often quarterly or semiannual for program metrics, with shorter intervals when therapy changes. How to read those trends without overreacting to noise is a separate design problem; see our earlier post on longevity biomarker testing and retesting trends.
Logistics brands need before the first kit ships
Panel design fails in operations as often as it fails on the menu. Confirm:
Who the ordering provider is in each state you serve
Whether members use at-home kits, a draw site, or both
How results route into your portal, API, or EMR
Critical-value handling and member messaging when something is urgent
Kit branding, inserts, and return shipping so round two looks like round one
Those logistics are what turn a biomarker list into a program members will repeat. If you are mapping markers to a white-label kit and results feed, IHDLab’s longevity lab testing page outlines how branded kits, CLIA testing in Irvine, and API or portal resulting fit that model.
Build the panel your clinicians will own, keep the first version focused, and design every marker for the next draw—not just the first screenshot.



